EC approves Dompe's Oxervate for keratitis

The European Commission approved an MAA from Dompe Farmaceutici S.p.A. (Milan, Italy) for Oxervate cenegermin to treat moderate to severe neurotrophic keratitis. The product is a recombinant human nerve growth factor (rhNGF) and has Orphan Drug status for the indication...